Skip to main content

Richard E. Pratley, MD

Richard E. Pratley, MD

Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute

Translational Research, Infectious Disease

Pratley

Overview

Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.

Articles

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

DIABETES THERAPY

2021

High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice

MICROBIOME

2021

A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function

CIRCULATION

2021

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

DIABETES CARE

2021

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from theLEADERandSUSTAIN6 clinical trials

DIABETES OBESITY & METABOLISM

2020

Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

DIABETES OBESITY & METABOLISM

2020

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials

DIABETES OBESITY & METABOLISM

2020

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

DIABETES CARE

2020

Pharmacological therapies to address obesity in type 1 diabetes

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY

2020

Risk of severe hypoglycaemia and its impact in type 2 diabetes inDEVOTE

DIABETES OBESITY & METABOLISM

2020

Education & Training

Education

Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn

Residency

University of Michigan, Ann Arbor, MI

Fellowship

University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT01942694

D2D: Vitamin D and Type 2 Diabetes

Icon for trial | D2D: Vitamin D and Type 2 Diabetes

Diabetes is a serious condition affecting about 1 in 10 people in the United States. Lifestyle changes, such as healthy eating, exercise and weight loss, can decrease the chances of developing diabetes. However, many people st ...

NCT01843127

GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Ex

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...

NCT01664624

ROF: A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

Icon for trial | ROF: A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Ar

You are being asked to participate in this study because you have type 2 diabetes and are being treated with metformin. Despite the availability of several different classes of medications to treat the diabetes, many patients a ...

NCT04016662

A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults with Type 1 Diabetes (Automated Insulin Delivery in Elderly with Type 1 Diabetes [AIDE t1D])

Icon for trial | AIDE: A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery (AID) Technologies on Hypoglycemia and Quality of Life (QOL) in Elderly Adults with Type 1 Diabetes (T1D)

This study is currently enrolling.

To determine how safe and effective hybrid closed-loop and predictive low glucose suspend insulin pump technologies are for patients aged 65 and older with type 1 diabetes, and learn the effect they have on hypoglycemia in this ...

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

Icon for trial | PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

This study is currently enrolling.

People with type 1 diabetes are at high risk of developing hypoglycemia because of insulin treatment and because their body is less effective at increasing the levels of sugar in their blood when it is low. In this research stu ...

RECODE: Researching Covid Outcomes in Diabetes

Icon for trial | RECODE: Researching Covid Outcomes in Diabetes

This study is currently enrolling.

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...

NCT04628481

DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...